EGFRvIII-positive glioblastoma patients were treated with Rindopepimut (a vaccination targeting the EGFR deletion mutation EGFRvIII) in addition to standard chemotherapy in 2017 randomized, double-blind, phase III trial (ClinicalTrials.gov, NCT01480479). The gene discussed is EGFR; the disease is glioblastoma.